Effect of Unani medicine for essential hypertensio

Phase 2

Completed

• Conditions: Health Condition 1: null- Stage I HYPERTENSIO

• Registration Number: CTRI/2017/08/009246
• Lead Sponsor: Jamia Hamdard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-03-12
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 57

Inclusion Criteria

Patients with essential hypertension (stage I hypertension based on JNC-7 classification) preferably patients with systolic 140 -155 and diastolic 90-95 mm Hg

Clinically stable patients

Patients of both genders

Patients not taking any anti-hypertensive drugs

Patients willing to sign the informed consent form and participate in the trial voluntarily

Exclusion Criteria

Stage II essential hypertension

Secondary hypertension

Diabetes mellitus and thyroid dysfunctions

Patients with acute infectious disease/s

Patients with systemic disorders like chronic liver, kidney or heart disease etc

Pregnant and lactating mothers

Terminally ill patients with infectious diseases like AIDS and Tuberculosis etc

Patients who fail to give consent

Patients who fail to follow up

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Systolic blood pressure reading <br/ ><br>Diastolic Blood Pressure reading <br/ ><br>IL-6 <br/ ><br>hs-CRPTimepoint: DAY ZERO, 21st DAY, 42nd DAY

Secondary Outcome Measures

Name	Time	Method
SIGN AND SYMPTOMS <br/ ><br>CBC WITH ESR <br/ ><br>LFT KFT LIPID PROFILE TSH BS F &PP URINE R/M ECG X RAY CHEST USG W/ATimepoint: DAY ZERO, 21ST DAY, 42ND DAY